Navigation Links
NIH selects LIAI for major study on allergy molecular causes and possible treatments
Date:11/13/2007

ght have an extremely powerful tool for treating allergy diseases.

LIAIs project efforts will be accelerated through bioinformatics along with the use of the allergy epitope information already in the IEDB. Bioinformatics uses computer databases, algorithms and statistical techniques to analyze biological information. We developed the IEDB and were going to take advantage of that huge resource to improve our epitope identification algorithms based on that data, said Bjoern Peters, Ph.D., project co-investigator. Well use those algorithms to statistically determine which allergy epitopes are most likely to trigger a T cell response and then test those assumptions in the lab. By using bioinformatics, we will greatly speed the development of the project data.


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution
2. Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution
3. deCODE discovers cause of major subtype of glaucoma
4. Bleeding, not inflammation, is major cause of early lung infection death
5. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
6. Leading experts cite poor health and nutrition as major barrier to education in developing world
7. Majority of Americans want local action on global warming, says poll
8. How schizophrenia develops: Major clues discovered
9. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. A study by the MUHC and McGill University opens a new door to understanding cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of California, San Francisco, researcher receives ASBMB-Merck Award 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 1CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 3CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 4CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 5CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 6CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 7CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 8CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 9CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 10CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 11CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 12CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 13CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 14CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 15Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 1Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 2Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15